Eli Lilly and Company announced the opening of the Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport dedicated to advancing Lilly’s efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration and chronic pain.
“The opening of LSC expands upon Lilly’s long-standing presence in the Boston area,” said Daniel Skovronsky, M.D., Ph.D., chief scientific officer and president, Lilly Research Laboratories, president, Lilly Immunology. “We are committed to being supportive neighbors in this hub of discovery and innovation, further collaborating with leading institutions and new talent to continue delivering transformative medicines for the people who need them most.”
LSC occupies 346,000 square feet in a 12-story building, developed and operated by Alexandria Real Estate Equities, Inc. (ARE), in the rapidly expanding Seaport district of Boston. The new site includes laboratories and office space and will also house the first Lilly Gateway Labs location on the East Coast, fostering a culture of shared expertise and real-time learning to accelerate the development of novel medicines. LSC will accommodate approximately 500 Lilly scientists and researchers, in addition to 200 people from the companies within Lilly Gateway Labs.
